Metagenomi, Inc. Common Stock
- Open
- 1.18
- Day high
- 1.19
- Day low
- 1.17
- Prev close
- 1.19
- Volume
- 107K
- Mkt cap
- $45M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.4
- P/S
- 3.3
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$9K over the last 3 months (0 open-market buys, 3 sales)
- 🏛Institutions reducing (13F)
Metagenomi, Inc. Common Stock (MGX) is a Healthcare company listed on NASDAQ. The stock is down 35% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 3 sales (SEC Form 4).
Metagenomi, Inc. Common Stock (MGX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
MGX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 10, 2026 | $-0.55 | $-0.73 | -32.0% | $-257000 | -108.5% |
| May 11, 2026 | $-0.60 | $-0.61 | -1.7% | $1M | -78.9% |
| Mar 5, 2026 | $-0.61 | $-0.60 | +1.0% | $4M | -46.6% |
| Nov 11, 2025 | $-0.60 | $-0.55 | +8.3% | $9M | +10.7% |
| Aug 12, 2025 | $-0.68 | $-0.54 | +20.6% | $9M | +7.2% |
| Mar 17, 2025 | $-0.62 | $-0.63 | -1.6% | $10M | +4.1% |
| Nov 13, 2024 | $-0.70 | $-0.45 | +35.7% | $12M | +70.3% |
| Aug 14, 2024 | $-0.59 | $-0.29 | +50.8% | $20M | +58.2% |
| Feb 10, 2024 | $-2.04 | $-0.51 | +74.8% | $12M | +6.9% |
| Jun 30, 2022 | — | $-1.57 | — | $3M | — |
| Mar 31, 2022 | — | $-1.57 | — | $3M | — |
MGX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 11, 2026 | Dere Willard Hdirector | Grant | 21,000 | $1.23 |
| Jun 11, 2026 | Reid Laurencedirector | Grant | 17,400 | $1.23 |
| Jun 11, 2026 | BJERKHOLT ERICdirector | Grant | 21,000 | $1.23 |
| Jun 11, 2026 | Eckhardt Juergendirector | Grant | 21,000 | $1.23 |
| Jun 10, 2026 | Wein Matthewofficer: See Remarks | Sell | 558 | $1.30 |
| Jun 10, 2026 | Wapnick Pamelaofficer: Chief Financial Officer | Sell | 2,884 | $1.30 |
| Jun 10, 2026 | Irish Jiandirector, officer: See Remarks | Sell | 3,737 | $1.30 |
| Apr 3, 2026 | Wapnick Pamelaofficer: Chief Financial Officer | Grant | 144,000 | $1.34 |
| Apr 3, 2026 | Wapnick Pamelaofficer: Chief Financial Officer | Grant | 24,000 | — |
| Apr 3, 2026 | Wein Matthewofficer: See Remarks | Grant | 68,000 | $1.34 |
| Apr 3, 2026 | Wein Matthewofficer: See Remarks | Grant | 11,000 | — |
| Apr 3, 2026 | Irish Jiandirector, officer: See Remarks | Grant | 276,000 | $1.34 |
| Apr 3, 2026 | Irish Jiandirector, officer: See Remarks | Grant | 46,000 | — |
| Mar 9, 2026 | Wapnick Pamelaofficer: Chief Financial Officer | Sell | 1,581 | $1.60 |
| Mar 9, 2026 | Wein Matthewofficer: See Remarks | Sell | 482 | $1.60 |
Source: MGX SEC Form 4 filings, latest Jun 11, 2026. For informational purposes only — not investment advice.
See the full MGX insider & 13F page →Metagenomi, Inc. Common Stock company profile
Overview
Metagenomi, Inc. (NASDAQ:MGX) is a gene editing biotechnology company founded in 2016 and headquartered in Emeryville, California. The company went public in 2006 and focuses on developing therapeutic treatments using advanced genome editing technologies derived from metagenomics research. Metagenomi has established strategic partnerships with major pharmaceutical companies including Moderna, Affini-T Therapeutics, and Ionis Pharmaceuticals to advance its gene editing platform for various therapeutic applications.
Business
Metagenomi operates in the gene editing biotechnology sector, which is a cutting-edge field within healthcare that involves precisely modifying DNA sequences to treat or prevent diseases. The company's core technology platform is built around a comprehensive genome editing toolbox that includes several sophisticated molecular tools for making targeted changes to genetic material. The company's primary offerings include programmable nucleases, which are molecular scissors that can cut DNA at specific locations; base editors, which allow for precise single-letter changes in the genetic code without cutting the DNA; and RNA and DNA-mediated integration systems. These integration systems include prime editing systems and CRISPR-associated transposases (CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats), which can insert new genetic material into specific locations in the genome. What makes Metagenomi unique is its use of metagenomics - the study of genetic material recovered from environmental samples - to discover and develop these editing tools. This approach allows the company to identify novel genome editing systems from nature that may be more precise, efficient, or suitable for specific therapeutic applications than existing technologies. The company operates primarily as a research and development organization, developing these tools for potential therapeutic applications in treating genetic diseases, cancer, and other conditions where precise genetic modifications could provide treatment benefits.
Revenue model
Metagenomi generates revenue primarily through strategic partnerships and licensing agreements with pharmaceutical and biotechnology companies. The company's business model centers on developing and licensing its proprietary genome editing technologies to partners who then use these tools to develop specific therapeutic products. The company has established several key revenue-generating partnerships. Its collaboration with ModernaTX focuses on developing new genome editing systems for in vivo human therapeutic applications, meaning treatments that would edit genes directly inside patients' bodies. The partnership with Affini-T Therapeutics involves developing gene-edited T-cell receptor-based therapeutic products for cancer treatment, where immune cells are modified outside the body and then reinfused into patients. Additionally, the Ionis Pharmaceuticals collaboration focuses on researching and developing investigational medicines using Metagenomi's genome editing technologies. Revenue from these partnerships typically comes in the form of upfront payments, milestone payments as development progresses, and potential royalties on any products that reach commercialization. In 2024, the company reported total revenue of $52.3 million, with quarterly revenues varying significantly based on milestone achievements and partnership activities. Factors that could increase the company's margins include successful advancement of partner programs triggering milestone payments, expansion of the partnership portfolio, and eventual royalty streams from commercialized products. Conversely, margins could be pressured by increased research and development costs, competitive pressure in the gene editing space from companies like CRISPR Therapeutics and Editas Medicine, and potential delays in partner programs that could defer milestone payments.
Risks & safety
The margin of safety appears moderate to weak given the company's cash burn rate and early-stage business model, though strong balance sheet metrics provide some cushion. • Cash burn and solvency: Free cash flow negative $112.2 million in 2024, with current cash of $27.4 million providing limited runway at current burn rates. However, strong current ratio of 6.9x and quick ratio of 6.9x indicate good short-term liquidity management. • Debt levels: Low debt-to-equity ratio of 0.19x indicates minimal financial leverage risk, providing flexibility for future financing needs. • Valuation metrics: Trading at 0.58x price-to-book ratio suggests potential undervaluation relative to assets, though negative earnings make traditional valuation difficult. Graham net-net ratio of 4.3x indicates the stock trades below liquidation value. • Other considerations: Partnership revenue provides some stability, but the company remains dependent on milestone achievements and faces typical biotech risks including regulatory approval uncertainties and competitive pressures.
Recent development
Based on the financial data trends, Metagenomi has been experiencing significant revenue volatility as it advances its partnership-based business model. Revenue increased from $17.2 million in 2022 to $44.8 million in 2023, then jumped to $52.3 million in 2024, indicating growing success in achieving partnership milestones and expanding collaborations. The company has been strategically focusing on high-value partnerships with established pharmaceutical companies rather than pursuing independent drug development. This approach is evident in its collaborations with Moderna for in vivo gene editing applications, Affini-T for cancer immunotherapy applications, and Ionis for investigational medicines, each targeting different therapeutic areas and applications of gene editing technology. Operational efficiency improvements are visible in the company's cost management, with R&D expenses appearing to be better controlled relative to revenue generation. The company has maintained its focus on expanding its genome editing toolbox through metagenomics research while simultaneously advancing multiple partnership programs. The company's cash management strategy has evolved from having substantial cash reserves of $184.4 million in 2022 to more modest levels of $27.4 million by 2024, suggesting either strategic deployment of capital for growth initiatives or higher operational expenses as programs advance. This trend indicates the company is actively investing in its technology platform and partnership development rather than maintaining large cash reserves.
MGX company profile · for informational purposes only — not investment advice.
Track MGX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free